A Phase I/II Study of BLU-451 in People with Non-Small Cell Lung Cancer


Full Title

Phase 1/2 Study of BLU-451 in Advanced Cancers with EGFR EXON20 Insertion Mutations


Researchers in this study want to find the highest dose of the investigational drug BLU-451 that can be given safely in people with advanced non-small cell lung cancer (NSCLC) that contains a mutation in the EGFR gene, which can cause cancer cells to grow. BLU-451 may inhibit NSCLC growth by blocking the mutated EGFR protein. It is taken orally (by mouth).


To be eligible for this study, patients must meet several requirements, including:

  • Participants must have EGFR-mutated NSCLC that is locally advanced or metastatic.
  • The serious side effects of previous treatments must go away before BLU-451 is given.
  • Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
  • This study is for people age 18 and older.


For more information and to ask about eligibility for this study, please contact the office of Dr. Helena Yu at 646-608-3912.